🔎 Trials Near Me

Home › Neuroendocrine Tumors › Kentucky

Pag-aaral pangklinika para sa Neuroendocrine Tumors sa Kentucky

7 pag-aaral para sa Neuroendocrine Tumors ang naghahanap ng mga kalahok sa mga site sa Kentucky.

Mga Lungsod sa Kentucky

Opisyal na teksto ng pag-aaral (English)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  • University of Kentucky Markey Cancer Center, Lexington
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06943755

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

  • University of Kentucky Medical Center, Lexington
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07087054

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

  • Research Facility, Lexington
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07165132

Project: Every Child for Younger Patients With Cancer

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 25 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT02402244

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

  • Crinetics Study Site, Lexington
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT07129252

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

  • University of Kentucky, Lexington
Nagre-recruitPhase 1/2
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update May 14, 2026 · NCT05636618

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

  • Research Facility, Lexington
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 30, 2026 · NCT05477576

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.